Earnings Call Summary | Aurinia Pharmaceuticals(AUPH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Aurinia Pharmaceuticals(AUPH.US) Q1 2024 Earnings Conference
The following is a summary of the Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript:
以下是奧瑞尼亞製藥公司（AUPH）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Aurinia reported Q1 net revenue of $50.3 million, marking a 46% YoY growth.
Net product revenue reached $48.1 million, equating to approximately 40% YoY growth.
The Company preserved its net product revenue guidance for FY 2024 of $200 million to $220 million.
Under a new restructuring initiative, Aurinia expects to reduce operating expenses by $50 million to $55 million over the next 12 months.
Going forward, the company aims to turn cash flow positive, excluding share repurchases, from Q2 2024.
The company ended the first quarter with cash, cash equivalents, and restricted cash, and investments totaling $320.1 million.
Aurinia公佈的第一季度淨收入爲5,030萬美元，同比增長46％。
淨產品收入達到4,810萬美元，相當於約40％的同比增長。
該公司維持了2024財年2億美元至2.2億美元的淨產品收入預期。
根據一項新的重組計劃，Aurinia預計將在未來12個月內將運營支出減少5000萬美元至5,500萬美元。
展望未來，該公司的目標是從2024年第二季度起將現金流轉爲正數，不包括股票回購。
該公司在第一季度末的現金、現金等價物和限制性現金以及總額爲3.201億美元的投資。
Business Progress:
業務進展：
Aurinia is focused on augmenting loop kinase revenues following a 25% workforce reduction.
In Q1, 448 patient start forms were added, and 148 new patients enrolled, showcasing significant YoY growth.
Aurinia is devising strategies for aggressive lupus nephritis treatment and reduction of proteinuria levels.
The company has launched an awareness campaign, 'Know the Signs,' to educate rheumatologists about the severity of lupus nephritis.
Aurinia is eagerly awaiting approval for LUPKYNIS in Japan, anticipated for H2 2024, which could yield a $10 million windfall and double-digit royalties on net sales.
The FDA granted approval for a label update on LUPKYNIS, signifying its safe and effective use in the long term.
The company purchased about $18.4 million worth of stock, planning to fund future purchases via discretionary purchase and repurchases through cash flows, excluding cash on hand.
IND for their April BAFF inhibitor, AUR200, was approved by the FDA, setting the stage for animal toxicity studies and clinical trials.
Lupus treatment guidelines conformity is seen as a key growth driver in the future.
在裁員25％之後，Aurinia專注於增加環路激酶的收入。
在第一季度，增加了448份患者起始表格，148名新患者入組，顯示出顯著的同比增長。
Aurinia正在設計治療侵襲性狼瘡腎炎和降低蛋白尿水平的策略。
該公司發起了一項名爲 “了解症狀” 的宣傳活動，以教育風溼病學家了解狼瘡腎炎的嚴重程度。
Aurinia熱切地等待LUPKYNIS在日本的批准，預計將在2024年下半年獲得批准，這可能會帶來1000萬美元的意外收入和兩位數的淨銷售特許權使用費。
美國食品和藥物管理局批准了LUPKYNIS的標籤更新，這表明其長期安全有效地使用。
該公司購買了價值約1,840萬美元的股票，計劃通過全權購買爲未來的購買提供資金，並通過現金流（不包括手頭現金）進行回購。
其四月份的BAFF抑制劑 AUR200 的IND已獲得美國食品藥品管理局的批准，爲動物毒性研究和臨床試驗奠定了基礎。
狼瘡治療指南的合規性被視爲未來的關鍵增長動力。
More details: Aurinia Pharmaceuticals IR
更多詳情： Aurinia 製藥公司 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。